.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Boehringer Ingelheim
Julphar
Merck
Mallinckrodt
Chubb
Baxter
Cerilliant
McKinsey
Citi

Generated: December 14, 2017

DrugPatentWatch Database Preview

Claims for Patent: 6,090,799

« Back to Dashboard

Claims for Patent: 6,090,799

Title: Method for ameliorating muscle weakness/wasting in a patient infected with human immunodeficiency virus-type 1
Abstract:A method for attenuating the HIV-associated myopathy and muscle wasting associated with infection by human immunodeficiency virus-Type 1. Administration of oxandrolone in a daily dosage of about 2.5 to about 20 milligrams is described.
Inventor(s): Berger; Joseph R. (Miami, FL)
Assignee: BTG Pharmaceuticals Corp. (Iselin, NJ)
Application Number:08/244,988
Patent Claims: 1. A method for ameliorating HIV-associated myopathy and muscle weakness in an AIDS patient which comprises orally administering oxandrolone to the AIDS patient in a daily dosage of between about 2.5 to about 7.5 milligrams.

2. The method in accordance with claim 1 wherein the daily dosage of the oxandrolone is about 7.5 milligrams.

3. The method in accordance with claim 1 wherein the oxandrolone is administered to said patient as a unit dose of about 1 to about 2.5 milligrams three times per day at about eight-hour intervals.

4. The method in accordance with claim 1 wherein the oxandrolone is administered in the form of a tablet.

5. The method in accordance with claim 1 wherein administration is continued over a period of about 2 weeks.

6. The method in accordance with claim 1 wherein administration is continued over a period of about 2 weeks.

7. The method in accordance with claim 3 wherein administration is continued over a period of about 2 weeks.

8. A method for ameliorating HIV-associated myopathy and muscle wasting in an AIDS patient which comprises orally administering a therapeutically effective amount of oxandrolone to the AIDS patient daily for a time period of about 2 weeks.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Daiichi Sankyo
Healthtrust
Fuji
Teva
McKinsey
Boehringer Ingelheim
Baxter
Julphar
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot